About Triglycerides
Ultra-low fat storage
Reference Values
Optimal Range
0 - 50 mg/dL
Women's Optimal Range
40.0 - 150.0 mg/dL
Elite Value
50 mg/dL
Health Implications
High
Elevated levels may indicate an increased risk for cardiovascular diseases and pancreatitis due to excess fatty acids in the blood.
Low
Low levels may be associated with malnutrition, hyperthyroidism, or liver diseases, potentially affecting energy reserves and overall metabolic health.
Symptoms
{'high': 'May include fatigue, abdominal pain, vomiting, skin changes, and pancreatitis symptoms such as nausea.', 'low': 'Can include fatigue, poor concentration, memory problems, and sometimes numbness in the extremities.'}
Lifestyle Factors
Specimen Type
Testing Methods
Also Known As
Scientific Sources
- 1. Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., ... & American Heart Association Clinical Lipidology, Lipoprotein, and Metabolism Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Preventive Cardiology. (2011). Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 123(20), 2292-2333.
- 2. Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., ... & European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. (2016). Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 37(25), 1944-1958.
- 3. Toth, P. P., Philip, S., Hull, M., Granowitz, C., & Anderson, A. (2019). Elevated triglycerides as a risk factor for cardiovascular disease in patients with statin-controlled LDL cholesterol: a review of current evidence. Cardiology in Review, 27(3), 140-146.
- 4. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., ... & Wiggins, L. E. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082-e1143.
- 5. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., ... & ESC Scientific Document Group. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111-188.